AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Bayer Gets UK Approval for Hot Flashes Treatment Lynkuet
ByAinvest
Thursday, Jul 10, 2025 12:04 pm ET1min read
Bayer has received UK approval to use elinzanetant, branded as Lynkuet, for treating moderate to severe hot flashes linked with menopause. This is the first global approval for the treatment. Elinzanetant demonstrated a favorable safety profile in three studies and submissions for marketing authorizations are underway in the US, EU, and other markets.
Bayer has received approval from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) to use elinzanetant, branded as Lynkuet, for treating moderate to severe hot flashes linked with menopause. This marks the first global approval for the treatment [1].Developed by Bayer, elinzanetant is a non-hormonal medication designed to alleviate the symptoms of menopause. It works by calming the signals in the brain that cause hot flushes and night sweats, a common symptom of menopause. The drug demonstrated a favorable safety profile in three studies and has been well-tolerated by patients [1].
The MHRA's approval comes after a thorough review of clinical trial data, which showed that elinzanetant significantly reduced hot flushes compared to a placebo. The drug was also linked to fewer sleep disturbances and reported improvements in quality of life among patients [1].
While elinzanetant is not yet available on the National Health Service (NHS) in the UK, it can be purchased privately. The MHRA has recommended that the drug be considered by the National Institute for Health and Care Excellence (NICE) for potential inclusion in the NHS [1].
Bayer is currently submitting marketing authorizations for elinzanetant in the US, EU, and other markets. The company expects that this approval will expand the treatment options for women experiencing menopause symptoms [2].
Menopause and perimenopause can significantly impact quality of life, with hot flushes being one of the most common and disruptive symptoms. The approval of elinzanetant offers a non-hormonal alternative for those who may not be able to, or prefer not to, take hormone-based therapies [1].
References:
[1] https://www.the-independent.com/news/health/hot-flush-pill-menopause-elinzanetant-lynkuet-bayer-b2784970.html
[2] https://www.marketscreener.com/quote/stock/BAYER-AG-436063/news/UK-Clears-Bayer-Medicine-for-Menopause-related-Hot-Flashes-50458178/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet